INSITE VSN!0.01 : InSite Vision Files IND for ISV-101 with the U.S. Food and Drug Administration for the Treatment of Dry Eye Disease (2024)

InSite Vision Incorporated (OTCBB:INSV) today announced that it has filed an Investigational New Drug (IND) application for ISV-101 with the U.S. Food and Drug Administration (FDA). ISV-101 is InSite Vision's novel compound being developed to treat dry eye disease, a widespread condition that is under-treated with currently available medicines. ISV-101 combines a low dose of the non-steroidal anti-inflammatory (NSAID) bromfenac (BROMDAY?/Xibrom? marketed by ISTA Pharmaceuticals) with InSite Vision's proprietary DuraSite® technology.

InSite Vision anticipates initiating a Phase 1/2 clinical trial in 2011 to evaluate the safety and efficacy of ISV-101 when administered twice daily to patients suffering from dry eye disease. The five-arm trial design will include three ISV-101 dose concentrations and comparisons against DuraSite and non-DuraSite (placebo) vehicles. Data from the Phase 1/2 study are expected to provide guidance on the ideal dose for ISV-101 and the design of a Phase 3 clinical program.

?I am proud of our team's ability to expand our clinical development pipeline by advancing this novel new drug candidate for the treatment of dry eye disease,? said Timothy Ruane, Chief Executive Officer of InSite Vision. ?Dry eye is a serious chronic condition, and the unique and proven attributes of our DuraSite technology, combined with the approved NSAID bromfenac, are expected to create an effective new therapy that improves the treatment of dry eye disease. With patent protection extending into 2029, we believe ISV-101 can be well positioned to compete in the expanding $500 million U.S. dry eye market.?

Dry eye disease occurs when the eye does not produce sufficient tears. While causes of dry eye may vary, it is frequently associated with inflammation of the surface of the eye, the lacrimal gland, or the conjunctiva. A potentially chronic condition that can occur at any age, dry eye disease is most prevalent among the elderly. It is estimated to affect five million people age 50 and older in the U.S. alone.1

ISV-101 incorporates a low concentration of bromfenac with InSite Vision's proven DuraSite polymer technology. DuraSite extends the duration of drug residence on the surface of the eye to facilitate better penetration, thereby potentially improving efficacy, safety and dosing of a given therapeutic. Initial data from clinical studies evaluating the combination of DuraSite with a higher dose of bromfenac have demonstrated a favorable safety profile. Due to its distinct mode of action, ISV-101 is expected to act as a complimentary treatment to Restasis® (marketed by Allergan, Inc.) for patients with dry eye disease. Restasis is currently the largest selling dry eye treatment in the United States for patients with chronic dry eye.

About DuraSite®

InSite's DuraSite sustained delivery technology is a patented synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a solution, gel or suspension and can be customized for delivering a wide variety of potential drug candidates. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1% and Besivance? (besifloxacin ophthalmic suspension) 0.6%. InSite vision is also applying DuraSite to multiple other clinical- and preclinical-stage product candidates to create a portfolio of novel ophthalmic products.

About InSite Vision

InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The company's product portfolio utilizes InSite Vision's proven DuraSite® bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Inspire Pharmaceuticals, and Besivance? (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch & Lomb and their partner Pfizer Inc. InSite Vision's clinical-stage ophthalmic product pipeline includes ISV-502 and ISV-305 for the treatment of eye infections, ISV-303 for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease. For further information on InSite Vision, please visit

Forward-looking Statements

This news release contains certain statements of a forward looking nature relating to future events, including, InSite's plans to initiate a Phase 1/2 clinical trial for ISV-101 and the timing thereof, expected indications for, and potential advantages of, ISV-101, the potential market size for ISV-101, the expected benefits of ISV-101 and plans for a subsequent Phase 3 trials for ISV-101. Such statements entail a number of risks and uncertainties, including but not limited to: the results of clinical trials for ISV-101; the timing of completion of the Phase 1/2 clinical trial, InSite's ability to obtain Food and Drug Administration (FDA) approval to commence additional clinical trials for ISV-101 and the timing thereof; InSite's reliance on third parties for the commercialization of its products; the ability of InSite to enter into corporate collaborations for its product candidates; InSite's ability to expand its product platform to include additional indications; InSite's ability to compete effectively, either alone or through its partners, with other companies offering competing products or treatments; InSite's ability to maintain and develop additional collaborations and commercial agreements with corporate partners, including those with respect to AzaSite; its ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others; and determinations by the FDA. Reference is made to the discussion of these and other risk factors detailed in InSite Vision's filings with the Securities and Exchange Commission, including its annual report on Form 10-K and its quarterly reports on Form 10-Q, under the caption "Risk Factors" and elsewhere in such reports. Any forward-looking statements or projections are based on the limited information currently available to InSite Vision, which is subject to change. Although any such forward-looking statements or projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release is still valid at any later date.

1 Source: National Eye Institute ?Facts About Dry Eye?

AzaSite® and DuraSite® are registered trademarks of InSite Vision Incorporated.

BROMDAY?/Xibrom? (bromfenac ophthalmic solution) 0.09%, is a trademark of ISTA Pharmaceuticals.

BESIVANCE? is a trademark of Bausch & Lomb Incorporated.

INSITE VSN!0.01 : InSite Vision Files IND for ISV-101 with the U.S. Food and Drug Administration for the Treatment of Dry Eye Disease (1)

InSite Vision
Louis Drapeau, 510-747-1220
Chief Financial Officer
BCC Partners
Michelle Corral, 415-794-8662

INSITE VSN!0.01 :  InSite Vision Files IND for ISV-101 with the U.S. Food and Drug Administration for the Treatment of Dry Eye Disease (2024)


What is the FDA approved treatment for dry eye disease? ›

Miebo (perfluorohexyloctane ophthalmic solution), formerly known as NOV03, is the only FDA-approved treatment for dry eye disease (DED) that directly targets tear evaporation. The FDA approved Miebo for the treatment of signs and symptoms of dry eye disease, Bausch + Lomb and Novaliq announced in a press release.

What is a non pharmacological treatment for dry eyes? ›

Using light therapy and eyelid massage.

A technique called intense-pulsed light therapy followed by massage of the eyelids may help people with severe dry eyes.

What is the new treatment approved for dry macular degeneration? ›

So, what are the latest treatments for dry macular? In 2023, the FDA approved two new drug options for patients suffering from the symptoms of dry AMD: Pegcetacoplan (Syfovre™) and Avacincaptad Pegol (IZERVAY™).

How serious is dry eye disease? ›

Your tears protect the surface of your eyes from infection. Without adequate tears, you may have an increased risk of eye infection. Damage to the surface of your eyes. If left untreated, severe dry eyes may lead to eye inflammation, abrasion of the corneal surface, corneal ulcers and vision loss.

How I cured my dry eyes permanently? ›

While there is no cure, there are ways to manage and alleviate the symptoms. Treatment options for dry eye include OTC artificial tears, supplements, compresses, and in rare cases, surgery. Consider speaking with a doctor if your dry eyes are severe or persistent.

Can Sjögren's affect your eyes? ›

When a person has Sjögren's syndrome, their immune system is attacking the glands that keep the eyes, mouth and other body parts moist. The severity of the disease can vary widely, but the most common symptoms are dry eyes and dry mouth. Dry eyes. Due to decreased tear production, your eyes may feel extremely dry.

How to unblock eye oil glands at home? ›

Putting warm, wet and clean washcloths over your eyelids for about five minutes to loosen the oil. Pressing gently on your eyes near the lashes, massaging the glands. Cleaning your eyelids and lashes with or without mild soap or baby shampoo. Taking omega-3 supplements in the form of fish oil or flaxseed oil.

What is the new treatment for dry eyes in 2024? ›

Harrow Announces Availability of VEVYE (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease. Published January 11, 2024.

What is the best prescription for dry eye disease? ›

For severe dry eye syndrome, your ophthalmologist may recommend that you use cyclosporine, known by the brand name Restasis®, an anti-inflammatory medicated eye drop designed for long-term use.

What is the new FDA approved eye injection? ›

EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) TARRYTOWN, N.Y. , Aug. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

Is IPL for dry eyes covered by insurance? ›

Which dry eye treatments are covered usually depends on your provider and insurance plan. Some providers may offer partial coverage for select services, but typically IPL, LipiFlow, and iLux are not covered.


Top Articles
Latest Posts
Article information

Author: Virgilio Hermann JD

Last Updated:

Views: 6312

Rating: 4 / 5 (61 voted)

Reviews: 84% of readers found this page helpful

Author information

Name: Virgilio Hermann JD

Birthday: 1997-12-21

Address: 6946 Schoen Cove, Sipesshire, MO 55944

Phone: +3763365785260

Job: Accounting Engineer

Hobby: Web surfing, Rafting, Dowsing, Stand-up comedy, Ghost hunting, Swimming, Amateur radio

Introduction: My name is Virgilio Hermann JD, I am a fine, gifted, beautiful, encouraging, kind, talented, zealous person who loves writing and wants to share my knowledge and understanding with you.